Horizon moves corporate base here
The Illinois-headquartered speciality pharmaceutical business, which makes treatments for unmet therapeutic needs in arthritis and inflammatory diseases, is to acquire Vidara Therapeutics for approximately $660m €475m) in a reverse stock and cash merger expected to close by the middle of this year.
Vidara has operations in Dublin and in the US and the newly enlarged company — to be named Horizon Pharma plc, with a Nasdaq stock listing — will result in a “tax efficient corporate structure … organised under the laws of Ireland, with a portfolio of four products marketed primarily in the US”.
